EXCLUSIVE: Enlivex Secures More Than $200 Million to Initiate First Public Company Prediction Markets Venture

Private Investment Announcement: Enlivex Therapeutics Ltd. announced a private investment in public equity of 212 million shares at $1.00 per share, expecting gross proceeds of approximately $212 million to fund its RAIN prediction markets token treasury strategy.

RAIN Protocol Overview: RAIN is a decentralized predictions and options protocol on the Arbitrum network, allowing users to create and trade custom options, with governance by the RAIN token featuring a deflationary Buyback & Burn mechanism.

Clinical Trial Results: Enlivex shared six-month efficacy data from its Phase 2a trial of Allocetra, showing significant reductions in pain and improvements in function for patients with moderate to severe knee osteoarthritis, particularly in those aged 60 and above.

Stock Performance: Following the announcements, ENLV stock rose by 6.84% to $0.96 during the premarket session.